Princeton Global Asset Management LLC Cuts Position in Kenvue Inc. $KVUE

Princeton Global Asset Management LLC decreased its stake in Kenvue Inc. (NYSE:KVUE) by 1.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 117,562 shares of the company’s stock after selling 1,269 shares during the period. Princeton Global Asset Management LLC’s holdings in Kenvue were worth $2,461,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in KVUE. CORDA Investment Management LLC. grew its position in Kenvue by 0.7% during the second quarter. CORDA Investment Management LLC. now owns 1,250,494 shares of the company’s stock worth $26,173,000 after buying an additional 8,465 shares during the period. Altus Wealth Group LLC boosted its stake in shares of Kenvue by 1.7% during the 2nd quarter. Altus Wealth Group LLC now owns 31,398 shares of the company’s stock worth $657,000 after acquiring an additional 524 shares in the last quarter. International Assets Investment Management LLC grew its holdings in shares of Kenvue by 115.5% in the 2nd quarter. International Assets Investment Management LLC now owns 22,082 shares of the company’s stock worth $462,000 after acquiring an additional 11,835 shares during the period. SAM Advisors LLC increased its stake in Kenvue by 3.1% in the 2nd quarter. SAM Advisors LLC now owns 58,192 shares of the company’s stock valued at $1,218,000 after purchasing an additional 1,724 shares in the last quarter. Finally, TrueMark Investments LLC increased its stake in Kenvue by 8.8% in the 2nd quarter. TrueMark Investments LLC now owns 229,648 shares of the company’s stock valued at $4,807,000 after purchasing an additional 18,623 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 8.4%

Shares of KVUE stock opened at $15.30 on Monday. The company has a market capitalization of $29.37 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 2.20 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $18.54 and a 200 day moving average price of $21.02. Kenvue Inc. has a twelve month low of $14.05 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period last year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a $0.2075 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 5.4%. Kenvue’s payout ratio is presently 112.16%.

Wall Street Analyst Weigh In

A number of analysts have commented on KVUE shares. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research report on Friday, September 26th. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. Finally, Barclays lowered their price target on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.